Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.62 |
| ▸ | CCR8 | P51685 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 10/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745071 | 0.96 | CCR1 (0.62) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL16715991 | 0.94 | CCR1 (0.67) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL4036263 | 0.88 | CCR1 (0.58) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL1457181 | 0.87 | CCR1 (0.57) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL3751824 | 0.87 | CCR1 (0.52) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL4037764 | 0.85 | CCR1 (0.50) | CCR1CCR8METAP2CYP2A6RAB9A | |
| SCHEMBL3754653 | 0.83 | CCR1 (0.52) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL196966 | 0.78 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL29388304 | 0.78 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL30511194 | 0.78 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | claimed |
| EP-2061785-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-05-27 | — | — | EP | claimed |
| WO-2008012441-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | claimed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | PPOX, PNPO, PLPBP | CCR1 3399/4885CCR8 3114/4885METAP2 294/4885 |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | CCR1 3696/4885CCR8 3435/4885METAP2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.